Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More
X
publication

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias


Thijssen, R. et al.
Blood (2021)
Abstract

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced clinically relevant responses in blood cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1 were applied. Strikingly, tumor cells with TP-53 dysfunction escaped and thrived over time if inhibition of BCL-2 or MCL-1 was sublethal, in part because of an increased threshold for BAX/BAK activation in these cells. Our study revealed the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconciled the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia. In contrast to BH3-mimetics targeting just BCL-2 or MCL-1 at doses that are individually sublethal, a combined BH3-mimetic approach targeting both prosurvival proteins enhanced lethality and durably suppressed the leukemia burden, regardless of TP53 mutation status. Our findings highlight the importance of using sufficiently lethal treatment strategies to maximize outcomes of patients with TP53-mutant disease. In addition, our findings caution against use of sublethal BH3-mimetic drug regimens that may enhance the risk of disease progression driven by emergent TP53-mutant clones.



Authors

Thijssen, R., Diepstraten, S.T., Moujalled, D., Chew, E., Flensburg, C., Shi, M.X., Dengler, M.A., Litalien, V., MacRaild, S., Chen, M., Anstee, N.S., Reljić, B., Gabriel, S.S., Djajawi, T.M., Riffkin, C.D., Aubrey, B.J., Chang, C., Tai, L., Xu, Z., Morley, T., Pomilio, G., Bruedigam, C., Kallies, A., Stroud, D.A., Bajel, A., Kluck, R.M., Lane, S.W., Schoumacher, M., Banquet, S., Majewski, I.J., Strasser, A., Roberts, A.W., Huang, D.C.S., Brown, F.C., Kelly, G.L., Wei, A.H.



VIEW

publication
Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation
Bowman RL
BioRxiv (2022)
publication
Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia
Guess T
Blood Cancer Discovery (2022)
publication
High-throughput single-cell sequencing for retroviral reservoir characterization
Droske LE
BioRxiv (2022)
publication
scTAM-seq enables targeted high-confidence analysis of DNA methylation in single cells
Bianchi A
BioRxiv (2022)
REQUEST QUOTE